Cho-Rong Bae Selected Research

CU06-1004

2/2024	CU06-1004 alleviates oxidative stress and inflammation on folic acid-induced acute kidney injury in mice.
4/2023	Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury.
1/2023	Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases.
5/2022	CU06-1004 modulates the adenosine monophosphate (AMP)-associated protein kinase (AMPK) signaling pathway and inhibits lipogenesis in 3T3-L1 adipocytes and high-fat diet-induced obese mice.
1/2021	Correction: The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.
1/2020	CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury.
1/2020	The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cho-Rong Bae Research Topics

Disease

8	Inflammation (Inflammations) 02/2024 - 01/2015
5	Insulin Resistance 05/2022 - 07/2014
4	Obesity 05/2022 - 01/2017
3	Fibrosis (Cirrhosis) 02/2024 - 09/2018
3	Body Weight (Weight, Body) 05/2022 - 01/2014
3	Alcoholic Fatty Liver 01/2021 - 09/2018
2	Hypoxia (Hypoxemia) 01/2023 - 10/2022
2	Glucose Intolerance 09/2014 - 07/2014
1	Acute Kidney Injury (Acute Renal Failure) 02/2024
1	Acute Lung Injury 04/2023
1	Pulmonary Edema 04/2023
1	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2023
1	Pathologic Processes 01/2023
1	Vascular Diseases (Vascular Disease) 01/2023
1	Blindness (Hysterical Blindness) 01/2023
1	Pathologic Neovascularization 10/2022
1	Chronic Disease (Chronic Diseases) 05/2022
1	Brain Ischemia (Cerebral Ischemia) 01/2020
1	Ischemia 01/2020
1	Reperfusion Injury 01/2020
1	Herpes Zoster 01/2020
1	Brain Edema (Cerebral Edema) 01/2020
1	Liver Diseases (Liver Disease) 09/2018
1	Dyslipidemias (Dyslipidemia) 09/2018
1	Hypertrophy 01/2018

Drug/Important Bio-Agent (IBA)

7	CU06-1004IBA 02/2024 - 01/2020
4	Glucose (Dextrose)FDA LinkGeneric 09/2018 - 09/2014
4	Insulin (Novolin)FDA Link 09/2018 - 01/2014
3	Choline (Choline Chloride)IBA 01/2021 - 09/2018
3	C-Type Natriuretic Peptide (Peptide, C-Type Natriuretic)IBA 09/2018 - 01/2017
2	Amino Acids FDA Link 01/2021 - 01/2020
2	LipidsIBA 01/2020 - 09/2018
2	CDAA (Randox)IBA 01/2020 - 09/2018
2	Fatty Acids (Saturated Fatty Acids)IBA 09/2018 - 01/2018
2	Triglycerides (Triacylglycerol)IBA 09/2018 - 01/2014
1	Folic Acid (Vitamin M)FDA LinkGeneric 02/2024
1	Transforming Growth Factors (Transforming Growth Factor)IBA 02/2024
1	Retinaldehyde (Retinal)IBA 01/2023
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023
1	Oxygen (Dioxygen)IBA 10/2022
1	CateninsIBA 10/2022
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	AcidsIBA 09/2018
1	Blood Glucose (Blood Sugar)IBA 09/2018
1	asparagine-oxo-acid aminotransferaseIBA 09/2018
1	CholesterolIBA 09/2018
1	Enterotoxin ReceptorsIBA 01/2015
1	guanylinIBA 01/2015
1	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 07/2014
1	LeptinIBA 01/2014

Therapy/Procedure

3	Oral Administration 01/2023 - 01/2020
1	Glycemic Control 09/2018